Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
Status:
Active, not recruiting
Trial end date:
2023-07-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the clinical activity of durvalumab alone vs
durvalumab in combination with novel agents. The overall study goal is early identification
of novel durvalumab combinations that are more active than durvalumab alone in the treatment
of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.